Therapeutic plasma exchange for myasthenia gravis, Guillain-Barre syndrome, and other immune-mediated neurological diseases, over a 40-year experience. (3rd October 2022)
- Record Type:
- Journal Article
- Title:
- Therapeutic plasma exchange for myasthenia gravis, Guillain-Barre syndrome, and other immune-mediated neurological diseases, over a 40-year experience. (3rd October 2022)
- Main Title:
- Therapeutic plasma exchange for myasthenia gravis, Guillain-Barre syndrome, and other immune-mediated neurological diseases, over a 40-year experience
- Authors:
- Fernández-Fournier, Mireya
Kerguelen, Ana
Rodríguez de Rivera, Francisco Javier
Lacruz, Laura
Jimeno, Santiago
Losantos, Itsaso
Hernández-Maraver, Dolores
Puertas, Inmaculada
Tallon-Barranco, Antonio
Viejo, Aurora
Frank García, Ana
Díez-Tejedor, Exuperio - Abstract:
- ABSTRACT: Background: Therapeutic plasma exchange (TPE) was first used in neurology in the 1980s for myasthenia gravis (MG) and Guillain-Barré syndrome (GBS). Indications have since grown. Fear of complications with this treatment modality limit its use. Research design & methods: A study of patients undergoing TPE for neurological diseases (1981–2020) in a University Hospital in Madrid, Spain. Clinical indications, complications, procedure number, apheresis technique and replacement fluids were prospectively recorded and retrospectively analyzed. Historical trends were studied. Results: 159 patients (48.69 ±18.15 years, 54.3% females) underwent TPE using central-venous catheter and replacement fluid albumin. We performed 1207 procedures over 189 cycles (6.4 ±3.8 procedures/cycle). Most patients underwent TPE for category I–II indications, mainly GBS and MG (77.7%). Complication rate was low (3.9% procedures), mostly hypotensive/vasovagal reactions (55.3%) and vascular access-related complications (38.3%). Most were mild-moderate (92.9%), permitting TPE completion, and somewhat more frequent during the first procedure (38.3%) and after periods of little TPE use. GBS patients were more prone to complications than MG patients (6.5% vs. 1.2%, p<0.001) mainly hypotensive/vasovagal reactions (3.7% vs. 1.0%, p=0.008). Conclusions: TPE is well-tolerated with low complication rate (<4% procedures), mainly hypotensive/vasovagal reactions. Patients with GBS seem more prone to themABSTRACT: Background: Therapeutic plasma exchange (TPE) was first used in neurology in the 1980s for myasthenia gravis (MG) and Guillain-Barré syndrome (GBS). Indications have since grown. Fear of complications with this treatment modality limit its use. Research design & methods: A study of patients undergoing TPE for neurological diseases (1981–2020) in a University Hospital in Madrid, Spain. Clinical indications, complications, procedure number, apheresis technique and replacement fluids were prospectively recorded and retrospectively analyzed. Historical trends were studied. Results: 159 patients (48.69 ±18.15 years, 54.3% females) underwent TPE using central-venous catheter and replacement fluid albumin. We performed 1207 procedures over 189 cycles (6.4 ±3.8 procedures/cycle). Most patients underwent TPE for category I–II indications, mainly GBS and MG (77.7%). Complication rate was low (3.9% procedures), mostly hypotensive/vasovagal reactions (55.3%) and vascular access-related complications (38.3%). Most were mild-moderate (92.9%), permitting TPE completion, and somewhat more frequent during the first procedure (38.3%) and after periods of little TPE use. GBS patients were more prone to complications than MG patients (6.5% vs. 1.2%, p<0.001) mainly hypotensive/vasovagal reactions (3.7% vs. 1.0%, p=0.008). Conclusions: TPE is well-tolerated with low complication rate (<4% procedures), mainly hypotensive/vasovagal reactions. Patients with GBS seem more prone to them than MG patients. Acquaintance with this technique seems necessary. … (more)
- Is Part Of:
- Expert review of neurotherapeutics. Volume 22:Number 10(2022)
- Journal:
- Expert review of neurotherapeutics
- Issue:
- Volume 22:Number 10(2022)
- Issue Display:
- Volume 22, Issue 10 (2022)
- Year:
- 2022
- Volume:
- 22
- Issue:
- 10
- Issue Sort Value:
- 2022-0022-0010-0000
- Page Start:
- 897
- Page End:
- 903
- Publication Date:
- 2022-10-03
- Subjects:
- Adverse effects -- autoimmune diseases -- neurology -- plasma exchange -- plasmapheresis
Neuropharmacology -- Periodicals
615.7805 - Journal URLs:
- http://www.expert-reviews.com/loi/ern ↗
http://www.future-drugs.com/loi/ern ↗
http://www.tandfonline.com/toc/iern20/current ↗
http://informahealthcare.com ↗ - DOI:
- 10.1080/14737175.2022.2147827 ↗
- Languages:
- English
- ISSNs:
- 1473-7175
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3842.002995
British Library DSC - BLDSS-3PM
British Library HMNTS - Digital store
British Library HMNTS - ELD Digital store - Ingest File:
- 24677.xml